NuVasive announced preliminary 4Q17 revenue of ~US $272.0MM, +0.3% vs. 4Q16, and full-year 2017 revenue of ~$1,030.0MM, +7% vs. 2016.
The company achieved the top-end of its full-year guidance that was revised in 3Q17 to reflect 3Q results, lingering effects from the hurricane in Puerto Rico and continued slow growth of U.S. procedure volumes.
Final financial results and 2018 guidance will be reported in mid-February. Guidance for 2018 will include an expected contribution from the 4Q17 acquisition of SafePassage, provider of intra-op neurophysiological monitoring services.
NuVasive announced preliminary 4Q17 revenue of ~US $272.0MM, +0.3% vs. 4Q16, and full-year 2017 revenue of ~$1,030.0MM, +7% vs. 2016.
The company achieved the top-end of its full-year guidance that was revised in 3Q17 to reflect 3Q results, lingering effects from the hurricane in Puerto Rico and continued slow growth of U.S. procedure...
NuVasive announced preliminary 4Q17 revenue of ~US $272.0MM, +0.3% vs. 4Q16, and full-year 2017 revenue of ~$1,030.0MM, +7% vs. 2016.
The company achieved the top-end of its full-year guidance that was revised in 3Q17 to reflect 3Q results, lingering effects from the hurricane in Puerto Rico and continued slow growth of U.S. procedure volumes.
Final financial results and 2018 guidance will be reported in mid-February. Guidance for 2018 will include an expected contribution from the 4Q17 acquisition of SafePassage, provider of intra-op neurophysiological monitoring services.
Copy to clipboard 
